4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 04 2021
Historique:
received: 12 01 2021
accepted: 06 04 2021
entrez: 16 4 2021
pubmed: 17 4 2021
medline: 23 11 2021
Statut: epublish

Résumé

Hyaluronan synthesis inhibitor 4-methylumbelliferone (4-MU) is a candidate of radiosensitizers which enables both anti-tumour and anti-metastasis effects in X-ray therapy. The curative effects under such 4-MU administration have been investigated in vitro; however, the radiosensitizing mechanisms remain unclear. Here, we investigated the radiosensitizing effects under 4-MU treatment from cell experiments and model estimations. We generated experimental surviving fractions of human fibrosarcoma cells (HT1080) after 4-MU treatment combined with X-ray irradiation. Meanwhilst, we also modelled the pharmacological effects of 4-MU treatment and theoretically analyzed the synergetic effects between 4-MU treatment and X-ray irradiation. The results show that the enhancement of cell killing by 4-MU treatment is the greatest in the intermediate dose range of around 4 Gy, which can be reproduced by considering intercellular communication (so called non-targeted effects) through the model analysis. As supposed to be the involvement of intercellular communication in radiosensitization, the oxidative stress level associated with reactive oxygen species (ROS), which leads to DNA damage induction, is significantly higher by the combination of 4-MU treatment and irradiation than only by X-ray irradiation, and the radiosensitization by 4-MU can be suppressed by the ROS inhibitors. These findings suggest that the synergetic effects between 4-MU treatment and irradiation are predominantly attributed to intercellular communication and provide more efficient tumour control than conventional X-ray therapy.

Identifiants

pubmed: 33859324
doi: 10.1038/s41598-021-87850-3
pii: 10.1038/s41598-021-87850-3
pmc: PMC8050271
doi:

Substances chimiques

Radiation-Sensitizing Agents 0
Hymecromone 3T5NG4Q468

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8258

Références

Radiat Environ Biophys. 2015 Aug;54(3):305-16
pubmed: 25956821
PLoS One. 2013;8(1):e54526
pubmed: 23349919
Nat Rev Cancer. 2009 May;9(5):351-60
pubmed: 19377507
Int J Mol Sci. 2015 Jan 23;16(2):2591-609
pubmed: 25625514
J Radiat Res. 2017 Nov 1;58(6):782-790
pubmed: 28595296
Radiat Res. 1994 Dec;140(3):366-74
pubmed: 7972689
Cancer Radiother. 2019 Oct;23(6-7):662-665
pubmed: 31473087
PLoS One. 2014 Nov 26;9(11):e114056
pubmed: 25426641
J Oral Maxillofac Pathol. 2016 Jan-Apr;20(1):162
pubmed: 27194883
Sci Rep. 2019 Jun 24;9(1):9103
pubmed: 31235776
Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):85-91
pubmed: 422420
Oncogene. 2008 Jan 17;27(4):434-40
pubmed: 17621264
Radiat Res. 2002 Nov;158(5):626-33
pubmed: 12385640
Mutat Res. 2008 Feb 1;638(1-2):139-45
pubmed: 17977565
Oncol Lett. 2019 Mar;17(3):3555-3561
pubmed: 30867797
Med Phys. 2017 Oct;44(10):5522-5532
pubmed: 28786486
J Transl Med. 2013 Sep 26;11:231
pubmed: 24066670
Oncol Lett. 2020 Apr;19(4):2801-2808
pubmed: 32218833
Mutat Res. 2011 Jan 10;706(1-2):59-64
pubmed: 21073884
J Radiat Res. 2019 May 1;60(3):298-307
pubmed: 31034058
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):829-33
pubmed: 22417807
Sci Rep. 2018 May 29;8(1):8287
pubmed: 29844494
Mol Cancer Res. 2008 Jan;6(1):78-88
pubmed: 18234964
Free Radic Biol Med. 2003 Jul 1;35(1):68-77
pubmed: 12826257
Redox Biol. 2015 Dec;6:396-400
pubmed: 26355395
Oncogene. 2004 Jan 15;23(2):535-45
pubmed: 14724581
Phytother Res. 2017 Sep;31(9):1369-1375
pubmed: 28675489
Eur J Cancer. 2002 Jan;38(2):223-30
pubmed: 11803139
Neoplasma. 2007;54(6):495-502
pubmed: 17949233
Radiat Prot Dosimetry. 2015 Sep;166(1-4):148-51
pubmed: 25877530
Mutat Res. 2015 Mar;773:43-7
pubmed: 25769186
Lancet. 2011 Nov 12;378(9804):1727-40
pubmed: 21565398
Int J Radiat Biol. 2015 May;91(5):452-8
pubmed: 25651038
Semin Radiat Oncol. 2008 Oct;18(4):234-9
pubmed: 18725109
J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):63-73
pubmed: 16900390
Int J Radiat Biol. 2001 Jun;77(6):655-64
pubmed: 11403705
J Pediatr Hematol Oncol. 2014 Apr;36(3):231-3
pubmed: 24276045
Biochim Biophys Acta Mol Cell Res. 2017 Jan;1864(1):177-190
pubmed: 27845209
J Pharm Pharmacol. 2008 Aug;60(8):943-50
pubmed: 18644187
Sci Rep. 2018 Mar 19;8(1):4849
pubmed: 29555939
Mutat Res. 2007 Mar 1;616(1-2):159-64
pubmed: 17134726
Radiat Prot Dosimetry. 2012 Nov;152(1-3):104-8
pubmed: 22940790
Biochem Biophys Res Commun. 2008 Feb 8;366(2):301-7
pubmed: 18035043
Free Radic Biol Med. 2012 Jul 15;53(2):260-70
pubmed: 22580337
J Radiat Res. 2019 Mar 1;60(2):163-170
pubmed: 30624744
Oncol Lett. 2017 Jan;13(1):410-416
pubmed: 28123575
Radiat Oncol. 2015 Nov 14;10:227
pubmed: 26572130
J Cancer Res Clin Oncol. 2015 Apr;141(4):575-89
pubmed: 25005789
Med Phys. 2015 Nov;42(11):6203-10
pubmed: 26520713
Front Immunol. 2015 Mar 23;6:123
pubmed: 25852691
Biochem Pharmacol. 2010 Dec 15;80(12):1904-14
pubmed: 20599771
Radiat Oncol. 2018 May 16;13(1):96
pubmed: 29769103
Cancer Lett. 2009 May 8;277(1):64-71
pubmed: 19117669
Sci Rep. 2019 Jul 1;9(1):9483
pubmed: 31263149
Cells. 2020 Apr 30;9(5):
pubmed: 32365916
Biochem Biophys Res Commun. 2011 Jul 22;411(1):102-6
pubmed: 21712027
Int J Mol Med. 2018 Mar;41(3):1731-1739
pubmed: 29328396
Med Phys. 2012 Nov;39(11):6791-5
pubmed: 23127073
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905

Auteurs

Ryo Saga (R)

Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori, 036-8564, Japan. sagar@hirosaki-u.ac.jp.

Yusuke Matsuya (Y)

Nuclear Science and Engineering Center, Research Group for Radiation Transport Analysis, Japan Atomic Energy Agency, 2-4 Shirakata, Tokai, Ibaraki, 319-1195, Japan.
Faculty of Health Sciences, Hokkaido University, Kita-12 Nishi-5, Kita-ku, Sapporo, Hokkaido, 060-0812, Japan.

Rei Takahashi (R)

Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori, 036-8564, Japan.

Kazuki Hasegawa (K)

Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori, 036-8564, Japan.

Hiroyuki Date (H)

Faculty of Health Sciences, Hokkaido University, Kita-12 Nishi-5, Kita-ku, Sapporo, Hokkaido, 060-0812, Japan.

Yoichiro Hosokawa (Y)

Department of Radiation Science, Graduate School of Health Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori, 036-8564, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH